Berberine attenuates inflammation and oxidative stress and modulates lymphocyte E‐NTPDase in acute hyperlipidemia

Author:

Alruhaimi Reem S.1,Siddiq Abduh Maisa23ORCID,Ahmeda Ahmad F.45ORCID,Bin‐Ammar Albandari6,Kamel Emadeldin M.7,Hassanein Emad H. M.8ORCID,Li Chen9,Mahmoud Ayman M.1011ORCID

Affiliation:

1. Department of Biology, College of Science Princess Nourah bint Abdulrahman University Riyadh Saudi Arabia

2. Department of Medical Laboratory Sciences, Immune Responses in Different Diseases Research Group, Faculty of Applied Medical Sciences King Abdulaziz University Jeddah Saudi Arabia

3. Center of Excellence in Genomic Medicine Research King Abdulaziz University Jeddah Saudi Arabia

4. Department of Basic Medical Sciences, College of Medicine Ajman University Ajman United Arab Emirates

5. Center of Medical and Bio‐allied Health Sciences Research Ajman University Ajman United Arab Emirates

6. Department of Clinical Nutrition, College of Applied Medical Sciences University of Hail Ha'il Saudi Arabia

7. Chemistry Department, Faculty of Science Beni‐Suef University Beni‐Suef Egypt

8. Department of Pharmacology & Toxicology, Faculty of Pharmacy Al‐Azhar University‐Assiut Branch Assiut Egypt

9. Department of Biology, Chemistry, Pharmacy Free University of Berlin Berlin Germany

10. Department of Life Sciences, Faculty of Science and Engineering Manchester Metropolitan University Manchester UK

11. Zoology Department, Physiology Division, Faculty of Science Beni‐Suef University Beni‐Suef Egypt

Abstract

AbstractHyperlipidemia is a common clinically encountered health condition worldwide that promotes the development and progression of cardiovascular diseases, including atherosclerosis. Berberine (BBR) is a natural product with acknowledged anti‐inflammatory, antioxidant, and metabolic effects. This study evaluated the effect of BBR on lipid alterations, oxidative stress, and inflammatory response in rats with acute hyperlipidemia induced by poloxamer‐407 (P‐407). Rats were pretreated with BBR (25 and 50 mg/kg) for 14 days and acute hyperlipidemia was induced by a single dose of P‐407 (500 mg/kg). BBR ameliorated hypercholesterolemia, hypertriglyceridemia, and plasma lipoproteins in P‐407‐adminsitered rats. Plasma lipoprotein lipase (LPL) activity was decreased, and hepatic 3‐hydroxy‐3‐methylglutaryl CoA (HMG‐CoA) reductase activity was enhanced in hyperlipidemic rats. The expression of low‐density lipoprotein receptor (LDL‐R) and ATP‐binding cassette transporter 1 (ABCA1) was downregulated in hyperlipidemic rats. BBR enhanced LPL activity, upregulated LDL‐R, and ABCA1, and suppressed HMG‐CoA reductase in P‐407‐administered rats. Pretreatment with BBR ameliorated lipid peroxidation, nitric oxide (NO), pro‐inflammatory mediators (interleukin [IL]‐6, IL‐1β, tumor necrosis factor [TNF]‐α, interferon‐γ, IL‐4 and IL‐18) and enhanced antioxidants. In addition, BBR suppressed lymphocyte ecto‐nucleoside triphosphate diphosphohydrolase (E‐NTPDase) and ecto‐adenosine deaminase (E‐ADA) as well as NO and TNF‐α release by macrophages isolated from normal and hyperlipidemic rats. In silico investigations revealed the binding affinity of BBR toward LPL, HMG‐CoA reductase, LDL‐R, PSK9, ABCA1, and E‐NTPDase. In conclusion, BBR effectively prevented acute hyperlipidemia and its associated inflammatory responses by modulating LPL, cholesterolgenesis, cytokine release, and lymphocyte E‐NTPDase and E‐ADA. Therefore, BBR is an effective and safe natural compound that might be employed as an adjuvant against hyperlipidemia and its associated inflammation.

Funder

Princess Nourah Bint Abdulrahman University

Publisher

Wiley

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3